Page last updated: 2024-08-24

triazoles and zoledronic acid

triazoles has been researched along with zoledronic acid in 51 studies

Research

Studies (51)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (1.96)	18.2507
2000's	23 (45.10)	29.6817
2010's	27 (52.94)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Enomoto, K	1
Aglietta, M; Cirillo, S; Gatti, M; Martincich, L; Montemurro, F; Regge, D; Russo, F	1
Harvey, HA	1
Aapro, M	1
Bhatnagar, AS; Evans, DB; Gasser, JA; Green, JR; Ingold, P; Rebmann, A; Shen, V	1
Beck, JT; Brufsky, A; Carroll, R; Harker, WG; Hohneker, J; Lacerna, L; Perez, EA; Petrone, S; Seidler, C; Tan-Chiu, E	1
Galid, A; Gnant, MF; Grampp, S; Hausmaninger, H; Jakesz, R; Kaessmann, H; Luschin-Ebengreuth, G; Menzel, C; Mittlboeck, M; Mlineritsch, B; Piswanger-Soelkner, JC; Schmid, M	1
Gralow, JR	1
Bundred, NJ; Campbell, ID; Coleman, RE; Davidson, N; DeBoer, RH; Eidtmann, H; Miller, JC; Monnier, A; Neven, P; Schenk, NL; von Minckwitz, G	1
Brufsky, A; Bundred, N; Coleman, R; Ericson, S; Hadji, P; Jin, L; Lambert-Falls, R; Mena, R; Perez, EA; Schenk, N	1
Bjelic-Radisic, V; Dubsky, P; Fitzal, F; Gnant, M; Greil, R; Jakesz, R; Kainberger, F; Kässmann, H; Kubista, E; Luschin-Ebengreuth, G; Marth, C; Menzel, C; Mittlböck, M; Mlineritsch, B; Piswanger-Sölkner, JC; Ploner, F; Samonigg, H; Seifert, M; Steger, G; Wohlmuth, P	1
Fricker, J	1
Bjelic-Radisic, V; Dubsky, P; Eidtmann, H; Fitzal, F; Fridrik, M; Gnant, M; Greil, R; Hubalek, M; Jakesz, R; Kwasny, W; Luschin-Ebengreuth, G; Marth, C; Menzel, C; Mlineritsch, B; Pöstlberger, S; Rücklinger, E; Samonigg, H; Schippinger, W; Seifert, M; Steger, G; Stierer, M; Tausch, C	1
Alberts, S; Dentchev, T; Hines, SL; Johnson, DB; Kahanic, S; Liu, H; Loprinzi, CL; Mazurczak, MA; Mincey, B; Nikcevich, DA; Perez, EA; Schaefer, PL; Sloan, JA	1
Botti, G; Chiodini, P; D'Aiuto, G; De Feo, G; De Maio, E; de Matteis, A; Di Maio, M; Di Rella, F; Esposito, G; Gallo, C; Gravina, A; Labonia, V; Landi, G; Morabito, A; Nuzzo, F; Pacilio, C; Perrone, F; Piccirillo, MC; Rossi, E	1
Bosserman, LD; Brufsky, AM; Caradonna, RR; Ericson, SG; Haley, BB; Jin, L; Jones, CM; Moore, HC; Perez, EA; Warsi, GM	1
Wenz, F	1
Aebi, S; Gelber, RD	1
Gerber, B; Reimer, T	1
Berruti, A; Buttigliero, C; Dogliotti, L	1
Dong, PW; Li, LN	1
Botteman, MF; Heeg, BMS; Kaura, S; Logman, JFS; van Hout, BA	1
Chetty, U; Wishart, GC	1
Smith, IE	1
Atherton, PJ; Dakhil, SR; Dalton, RJ; Hines, SL; Johnson, DB; Loprinzi, CL; Mattar, BI; Perez, EA; Reddy, PS; Sloan, JA	1
Coleman, RE; Holen, I; Neville-Webbe, HL	1
Fox, KR	1
Bundred, N; Coleman, R; Davidson, N; de Boer, R; Eidtmann, H; Llombart-Cussac, A; Miller, J; Neven, P; Schenk, N; von Minckwitz, G	1
Beckmann, MW; Gnant, M; Jonat, W; Kreienberg, R; Lux, MP; Reichelt, C; Thiel, FC; Wallwiener, D	1
Tang, SC	1
Bauernhofer, T; Dubsky, P; Eidtmann, H; Eiermann, W; Fesl, C; Forsthuber, EP; Gnant, M; Greil, R; Heck, D; Hochreiner, G; Hubalek, M; Jakesz, R; Kwasny, W; Luschin-Ebengreuth, G; Menzel, C; Mlineritsch, B; Pristauz, G; Seifert, M; Steger, G; Stoeger, H	1
Argonza-Aviles, E; Beck, JT; Bosserman, L; Brufsky, AM; Ericson, SG; Harker, WG; Hohneker, J; Jin, L; Perez, EA; Seidler, C; Vogel, C; Warsi, G	1
Deleu, I; Frassoldati, A; Jerusalem, G; Llombart, A; Mebis, J; Miller, J; Neven, P; Paija, O; Schenk, N; Sleeboom, HP	1
Bernstein-Molho, R; Geffen, DB; Greenberg, J; Inbar, MJ; Pelles-Avraham, S; Safra, T; Sarid, D; Stemmer, SM; Stephansky, I	1
Fukunaga, M; Horiguchi, J; Hozumi, Y; Ishikawa, T; Iwase, T; Kohno, N; Nakamura, S; Noguchi, S; Taguchi, T; Takahashi, M; Takahashi, S	1
Bartiromo, A; Botti, G; Buonfanti, G; Colantuoni, G; D'Aiuto, M; D'Aniello, R; Daniele, G; De Feo, G; De Laurentiis, M; De Maio, E; de Matteis, A; Di Bonito, M; Di Maio, M; Di Rella, F; Esposito, G; Gallo, C; Giordano, P; Gravina, A; Labonia, V; Landi, G; Lastoria, S; Maiolino, P; Morabito, A; Normanno, N; Nuzzo, F; Pacilio, C; Perrone, F; Piccirillo, MC; Rossi, E; Signoriello, S; Tinessa, V	1
Brodie, AH; Nemieboka, BE; Schech, AJ	1
Barrios, C; Bundred, N; Campbell, I; Coleman, R; Davidson, N; de Boer, R; Eidtmann, H; Forbes, J; Frassoldati, A; Llombart, A; Martin, N; Modi, A; Neven, P; Paija, O; Sleeboom, HP; von Minckwitz, G	1
Akinci, MB; Aksoy, S; Altundag, K; Ozdemir, NY; Sendur, MA; Zengin, N	1
Kuranishi, F; Ohno, T	1
Baier, M; Beckmann, MW; Berghorn, M; Fasching, PA; Grab, D; Hanf, V; Hauschild, M; Jud, SM; Kahlert, S; Kreienberg, R; Krocker, J; Kühn, T; Kümmel, S; Lux, MP; Müller, T; Muth, M; Paepke, S; Schulz-Wendtland, R; Schütte, M; Stickeler, E; Wackwitz, B; Warm, M; Wolf, C	1
Guo, RT; Li, XL; Li, Y; Luan, JW; Nie, D; Wu, J; You, QS; Zhang, LP	1
Balic, M; Bartsch, R; Bjelic-Radisic, V; Dubsky, P; Eidtmann, H; Eiermann, W; Fesl, C; Fitzal, F; Gnant, M; Greil, R; Hochreiner, G; Jakesz, R; Knauer, M; Kwasny, W; Luschin-Ebengreuth, G; Mlineritsch, B; Moik, M; Ploner, F; Seifert, M; Selim, U; Sevelda, P; Steger, G; Stoeger, H; Taucher, S; Wette, V	1
Ikeda, T; Minato, N; Shimizu, A; Sugie, T; Sumi, E; Suzuki, E; Tada, H; Tanaka, Y; Teramukai, S; Toi, M; Yoshimura, K	1
Cheng, J; Hong, Q; Jia, X; Lei, L; Li, D; Li, J; Liu, G; Mo, M; Shao, Z; Shen, Z; Wang, Y	1
Dakhil, SR; Hines, SL; Kearns, AE; Lafky, JM; Liu, H; Loprinzi, CL; Perez, EA; Puttabasavaiah, S; Sloan, JA; Wagner-Johnston, ND	1
Atherton, PJ; Dakhil, SR; Hines, SL; Lafky, JM; Loprinzi, CL; Majithia, N; Olson, J; Perez, EA; Wagner-Johnston, N	1
Guise, TA; Harhash, AA; John, SK; Kozlow, WM; Marks, AR; Mohammad, KS; Murthy, S; Niewolna, M; Regan, JN; She, Y; Waning, DL; Wright, LE	1
Bassa, P; Capdevila, L; Garcia, JR; Pérez, C; Ramos, F; Valenti, V	1
Gondo, N; Hamazaki, Y; Ikeda, T; Kanao, S; Masuda, N; Minato, N; Sugie, T; Sumi, E; Suzuki, E; Tada, H; Tanaka, Y; Toi, M; Uozumi, R; Yamagami, K; Yamauchi, A	1

Reviews

4 review(s) available for triazoles and zoledronic acid

Article	Year
[New drugs in metastatic breast cancer--1997]. Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:13 Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Aromatase Inhibitors; Breast Neoplasms; Bridged-Ring Compounds; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Diphosphonates; Drug Resistance, Multiple; Female; Humans; Ibandronic Acid; Imidazoles; Letrozole; Nitriles; Tamoxifen; Taxoids; Triazoles; Zoledronic Acid	1997
Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy. Seminars in oncology, 2004, Volume: 31, Issue:6 Suppl 12 Topics: Antineoplastic Agents; Aromatase Inhibitors; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Letrozole; Nitriles; Pamidronate; Postmenopause; Triazoles; Zoledronic Acid	2004
Improving bone health in patients with early breast cancer by adding bisphosphonates to letrozole: the Z-ZO-E-ZO-FAST program. Breast (Edinburgh, Scotland), 2006, Volume: 15 Suppl 1 Topics: Aromatase Inhibitors; Bone Density; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Imidazoles; Letrozole; Nitriles; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; Triazoles; Zoledronic Acid	2006
Women and bone health: maximizing the benefits of aromatase inhibitor therapy. Oncology, 2010, Volume: 79, Issue:1-2 Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Breast Neoplasms; Colorectal Neoplasms; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Letrozole; Nitriles; Osteoporosis; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; RANK Ligand; Secondary Prevention; Tamoxifen; Triazoles; Zoledronic Acid	2010

Trials

25 trial(s) available for triazoles and zoledronic acid

Article	Year
Zoledronic acid prevents cancer treatment-induced bone loss. Oncology (Williston Park, N.Y.), 2005, Volume: 19, Issue:3 Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Female; Goserelin; Humans; Imidazoles; Nitriles; Premenopause; Tamoxifen; Triazoles; Zoledronic Acid	2005
Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Mar-01, Volume: 25, Issue:7 Topics: Adult; Aged; Alkaline Phosphatase; Bone Density; Breast Neoplasms; Collagen Type I; Diphosphonates; Female; Humans; Imidazoles; Letrozole; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Peptides; Triazoles; Zoledronic Acid	2007
Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Mar-01, Volume: 25, Issue:7 Topics: Adult; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Diphosphonates; Female; Goserelin; Humans; Imidazoles; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Tamoxifen; Triazoles; Zoledronic Acid	2007
Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. Cancer, 2008, Mar-01, Volume: 112, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Letrozole; Lumbar Vertebrae; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Triazoles; Zoledronic Acid	2008
Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. The oncologist, 2008, Volume: 13, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Letrozole; Lumbar Vertebrae; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Triazoles; Zoledronic Acid	2008
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. The Lancet. Oncology, 2008, Volume: 9, Issue:9 Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Female; Goserelin; Humans; Imidazoles; Linear Models; Nitriles; Osteoporosis; Premenopause; Prospective Studies; Tamoxifen; Triazoles; Zoledronic Acid	2008
Endocrine therapy plus zoledronic acid in premenopausal breast cancer. The New England journal of medicine, 2009, Feb-12, Volume: 360, Issue:7 Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Disease-Free Survival; Drug Therapy, Combination; Estrogen Antagonists; Female; Follow-Up Studies; Goserelin; Humans; Imidazoles; Middle Aged; Nitriles; Premenopause; Receptors, Estrogen; Tamoxifen; Triazoles; Zoledronic Acid	2009
Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC. Breast cancer research and treatment, 2009, Volume: 117, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Letrozole; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Tamoxifen; Triazoles; Zoledronic Acid	2009
Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Jul-01, Volume: 27, Issue:19 Topics: Aged; Antineoplastic Agents; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Dehydroepiandrosterone Sulfate; Diphosphonates; Estradiol; Female; Follicle Stimulating Hormone; Humans; Hydrocortisone; Imidazoles; Letrozole; Luteinizing Hormone; Middle Aged; Nitriles; Postmenopause; Progesterone; Receptors, Estrogen; Tamoxifen; Testosterone; Triazoles; Zoledronic Acid	2009
Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clinical breast cancer, 2009, Volume: 9, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Osteoporosis, Postmenopausal; Prognosis; Survival Rate; Treatment Outcome; Triazoles; Zoledronic Acid	2009
Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy. Breast (Edinburgh, Scotland), 2010, Volume: 19, Issue:2 Topics: Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Female; Humans; Imidazoles; Letrozole; Nitriles; Osteoporosis; Risk Factors; Treatment Outcome; Triazoles; Zoledronic Acid	2010
Adding zoledronic acid to endocrine therapy in the adjuvant treatment of hormone-sensitive breast cancer in premenopausal women: a new care standard or a provocative idea? Current oncology reports, 2010, Volume: 12, Issue:1 Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Drug Therapy, Combination; Female; Humans; Imidazoles; Neoplasms, Hormone-Dependent; Nitriles; Premenopause; Prognosis; Survival Rate; Tamoxifen; Triazoles; Zoledronic Acid	2010
Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Drug Therapy, Combination; Female; Humans; Imidazoles; Letrozole; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Postmenopause; Survival Rate; Time Factors; Treatment Outcome; Triazoles; Zoledronic Acid	2010
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. The Lancet. Oncology, 2011, Volume: 12, Issue:7 Topics: Adult; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Disease-Free Survival; Female; Follow-Up Studies; Humans; Imidazoles; Middle Aged; Neoplasm Staging; Nitriles; Premenopause; Tamoxifen; Treatment Outcome; Triazoles; Zoledronic Acid	2011
Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer, 2012, Mar-01, Volume: 118, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Bone and Bones; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Letrozole; Middle Aged; Nitriles; Organ Size; Osteoporosis, Postmenopausal; Postmenopause; Triazoles; Zoledronic Acid	2012
Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial. Clinical breast cancer, 2012, Volume: 12, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Imidazoles; Letrozole; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Receptors, Estrogen; Treatment Outcome; Triazoles; Zoledronic Acid	2012
The protective effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole: a prospective, randomized, phase II trial. Oncology, 2011, Volume: 81, Issue:5-6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Imidazoles; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Osteoporosis, Postmenopausal; Prospective Studies; Tamoxifen; Triazoles; Zoledronic Acid	2011
Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole: 12-month results. Breast cancer research and treatment, 2012, Volume: 133, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Female; Humans; Imidazoles; Japan; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Treatment Outcome; Triazoles; Zoledronic Acid	2012
Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study. Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Estradiol; Female; Humans; Imidazoles; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Tamoxifen; Triazoles; Zoledronic Acid	2012
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Imidazoles; Letrozole; Lumbar Vertebrae; Middle Aged; Nitriles; Postmenopause; Triazoles; Zoledronic Acid	2013
FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients. BMC cancer, 2014, Feb-05, Volume: 14 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Letrozole; Middle Aged; Neoadjuvant Therapy; Nitriles; Prospective Studies; Triazoles; Zoledronic Acid	2014
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:2 Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Female; Follow-Up Studies; Goserelin; Humans; Imidazoles; Kaplan-Meier Estimate; Middle Aged; Nitriles; Premenopause; Tamoxifen; Triazoles; Zoledronic Acid	2015
Effects of zoledronic acid and the association between its efficacy and γδT cells in postmenopausal women with breast cancer treated with preoperative hormonal therapy: a study protocol. Journal of translational medicine, 2014, Nov-25, Volume: 12 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Protocols; Diphosphonates; Female; Humans; Imidazoles; Letrozole; Nitriles; Postmenopause; Preoperative Care; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes; Triazoles; Zoledronic Acid	2014
5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial. Cancer, 2015, Aug-01, Volume: 121, Issue:15 Topics: Aged; Antineoplastic Agents; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Breast Neoplasms, Male; Chemotherapy, Adjuvant; Diphosphonates; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Imidazoles; Letrozole; Male; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Postmenopause; Tamoxifen; Triazoles; Zoledronic Acid	2015
Combined effects of neoadjuvant letrozole and zoledronic acid on γδT cells in postmenopausal women with early-stage breast cancer. Breast (Edinburgh, Scotland), 2018, Volume: 38 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Female; Humans; Imidazoles; Intraepithelial Lymphocytes; Letrozole; Middle Aged; Neoadjuvant Therapy; Nitriles; Postmenopause; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Treatment Outcome; Triazoles; Zoledronic Acid	2018

Other Studies

22 other study(ies) available for triazoles and zoledronic acid

Article	Year
Dynamic contrast enhanced magnetic resonance imaging in monitoring bone metastases in breast cancer patients receiving bisphosphonates and endocrine therapy. Acta radiologica (Stockholm, Sweden : 1987), 2004, Volume: 45, Issue:1 Topics: Adult; Aged; Anastrozole; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Goserelin; Humans; Imidazoles; Letrozole; Magnetic Resonance Imaging; Middle Aged; Nitriles; Pamidronate; Pilot Projects; Prospective Studies; Tamoxifen; Triazoles; Zoledronic Acid	2004
A single intravenous administration of zoledronic acid prevents the bone loss and mechanical compromise induced by aromatase inhibition in rats. Bone, 2006, Volume: 39, Issue:4 Topics: Animals; Aromatase Inhibitors; Biomechanical Phenomena; Body Weight; Bone and Bones; Bone Density; Bone Density Conservation Agents; Diphosphonates; Estrogens; Female; Imidazoles; Injections, Intravenous; Letrozole; Nitriles; Organ Size; Osteocalcin; Osteoporosis; Ovariectomy; RANK Ligand; Rats; Rats, Wistar; Triazoles; Uterus; Zoledronic Acid	2006
Bone density in breast cancer: when to intervene? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Aug-01, Volume: 25, Issue:22 Topics: Absorptiometry, Photon; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Diphosphonates; Female; Fractures, Bone; Goserelin; Humans; Imidazoles; Nitriles; Osteoporosis; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles; Zoledronic Acid	2007
San Antonio Breast Cancer Symposium. The Lancet. Oncology, 2009, Volume: 10, Issue:1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Diphosphonates; Everolimus; Female; Humans; Imidazoles; Lapatinib; Letrozole; Nitriles; Quinazolines; Sirolimus; Tamoxifen; Trastuzumab; Triazoles; Zoledronic Acid	2009
Endocrine therapy plus zoledronic acid in premenopausal breast cancer. The New England journal of medicine, 2009, May-28, Volume: 360, Issue:22 Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms; Data Interpretation, Statistical; Diphosphonates; Disease-Free Survival; Drug Therapy, Combination; Female; Goserelin; Humans; Imidazoles; Nitriles; Premenopause; Tamoxifen; Triazoles; Zoledronic Acid	2009
Endocrine therapy plus zoledronic acid in premenopausal breast cancer. The New England journal of medicine, 2009, May-28, Volume: 360, Issue:22 Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Drug Therapy, Combination; Female; Goserelin; Humans; Imidazoles; Nitriles; Premenopause; Tamoxifen; Triazoles; Zoledronic Acid	2009
Endocrine therapy plus zoledronic acid in premenopausal breast cancer. The New England journal of medicine, 2009, May-28, Volume: 360, Issue:22 Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Confidence Intervals; Diphosphonates; Disease-Free Survival; Drug Therapy, Combination; Female; Humans; Imidazoles; Nitriles; Premenopause; Tamoxifen; Triazoles; Zoledronic Acid	2009
Endocrine therapy plus zoledronic acid in premenopausal breast cancer. The New England journal of medicine, 2009, May-28, Volume: 360, Issue:22 Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Drug Therapy, Combination; Humans; Imidazoles; Nitriles; Premenopause; Triazoles; Vitamin D; Vitamins; Zoledronic Acid	2009
Endocrine therapy plus zoledronic acid in premenopausal breast cancer. The New England journal of medicine, 2009, May-28, Volume: 360, Issue:22 Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Drug Therapy, Combination; Female; Goserelin; Humans; Imidazoles; Nitriles; Premenopause; Receptor, ErbB-2; Tamoxifen; Triazoles; Zoledronic Acid	2009
Economic evaluation of zoledronic acid for the prevention of osteoporotic fractures in postmenopausal women with early-stage breast cancer receiving aromatase inhibitors in the UK. Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:7 Topics: Aged; Aged, 80 and over; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Cohort Studies; Cost-Benefit Analysis; Diphosphonates; Female; Humans; Imidazoles; Letrozole; Markov Chains; Middle Aged; Neoplasm Staging; Nitriles; Osteoporosis, Postmenopausal; Quality-Adjusted Life Years; Salvage Therapy; Survival Rate; Treatment Outcome; Triazoles; Zoledronic Acid	2010
Introduction to sessions on guidelines and endocrine therapy, the influence of breast screening on number of mastectomies and the challenge between molecular science and traditional dogma in the treatment of breast cancer. Introduction to Session 6. Breast cancer research : BCR, 2009, Volume: 11 Suppl 3 Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Letrozole; Mass Screening; Mastectomy; Nitriles; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles; Zoledronic Acid	2009
Do BIG1-98 and ZOFAST demand a change in guidelines for endocrine therapy? Breast cancer research : BCR, 2009, Volume: 11 Suppl 3 Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Letrozole; Nitriles; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles; Zoledronic Acid	2009
Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction. British journal of cancer, 2010, Mar-16, Volume: 102, Issue:6 Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diphosphonates; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Synergism; Female; Humans; Imidazoles; Letrozole; Nitriles; Triazoles; Zoledronic Acid	2010
Results of the Zometa cost-utility model for the german healthcare system based on the results of the ABCSG-12 study. Onkologie, 2010, Volume: 33, Issue:7 Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Breast Neoplasms; Cost-Benefit Analysis; Diphosphonates; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Costs; Female; Germany; Goserelin; Humans; Imidazoles; Markov Chains; Monte Carlo Method; Multicenter Studies as Topic; National Health Programs; Neoplasms, Multiple Primary; Nitriles; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles; Zoledronic Acid	2010
Zoledronic acid inhibits aromatase activity and phosphorylation: potential mechanism for additive zoledronic acid and letrozole drug interaction. The Journal of steroid biochemistry and molecular biology, 2012, Volume: 132, Issue:3-5 Topics: Aromatase; Aromatase Inhibitors; Cell Survival; Diphosphonates; Drug Synergism; Estradiol; Female; Humans; Imidazoles; Letrozole; MCF-7 Cells; Microsomes; Nitriles; Phosphorylation; Pregnancy; RNA Stability; Serine; Triazoles; Zoledronic Acid	2012
Does zoledronic acid have additive effect on suppression of plasma estrogen levels? Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:1 Topics: Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Drug Synergism; Estrogens; Female; Humans; Imidazoles; Letrozole; Nitriles; Triazoles; Zoledronic Acid	2013
Eradication of breast cancer with bone metastasis by autologous formalin-fixed tumor vaccine (AFTV) combined with palliative radiation therapy and adjuvant chemotherapy: a case report. World journal of surgical oncology, 2013, Jun-04, Volume: 11 Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Autoantigens; Bone Neoplasms; Breast Neoplasms; Cancer Vaccines; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Diphosphonates; Epirubicin; Female; Fixatives; Fluorouracil; Formaldehyde; Humans; Imidazoles; Magnetic Resonance Imaging; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Prognosis; Radiotherapy Dosage; Tomography, Emission-Computed, Single-Photon; Triazoles; Zoledronic Acid	2013
[Long-term results of personalized treatment in 72 breast cancer patients who failed chemotherapy]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2013, Volume: 35, Issue:12 Topics: Adult; Aged; Aromatase Inhibitors; Bone Density Conservation Agents; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Diphosphonates; Drugs, Chinese Herbal; Female; Follow-Up Studies; Humans; Imidazoles; Letrozole; Lung Neoplasms; Medicine, Chinese Traditional; Middle Aged; Neoplasm Staging; Nitriles; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Remission Induction; Retrospective Studies; Survival Rate; Treatment Failure; Triazoles; Zoledronic Acid	2013
Basal and therapy-driven hypoxia-inducible factor-1α confers resistance to endocrine therapy in estrogen receptor-positive breast cancer. Oncotarget, 2015, Apr-20, Volume: 6, Issue:11 Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Diphosphonates; Drug Resistance, Neoplasm; Estradiol; Estrogens; Female; Fulvestrant; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Imidazoles; Letrozole; MAP Kinase Signaling System; Mice; Mice, Nude; Neoadjuvant Therapy; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Neovascularization, Pathologic; Nitriles; Postmenopause; Receptors, Estrogen; RNA Interference; RNA, Small Interfering; Transcription, Genetic; Treatment Outcome; Triazoles; Xenograft Model Antitumor Assays; Zoledronic Acid	2015
Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2016, Volume: 24, Issue:3 Topics: Adjuvants, Pharmaceutic; Aged; Aged, 80 and over; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Imidazoles; Letrozole; Lumbar Vertebrae; Middle Aged; Nitriles; Osteoporosis; Triazoles; Zoledronic Acid	2016
Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo. Oncotarget, 2017, Jan-31, Volume: 8, Issue:5 Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Diphosphonates; Disease Progression; Estradiol; Female; Humans; Imidazoles; Letrozole; Mice, Inbred BALB C; Mice, Nude; Muscle Strength; Muscle Weakness; Muscle, Skeletal; Nitriles; Osteolysis; Ovariectomy; Receptors, Estrogen; Time Factors; Triazoles; Tumor Burden; Tumor Microenvironment; Xenograft Model Antitumor Assays; Zoledronic Acid	2017
18F-FDG PET/CT in the Staging and Management of Breast Cancer: Value in Disease Outcome and Planning Therapy. Clinical nuclear medicine, 2017, Volume: 42, Issue:3 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Axilla; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Diphosphonates; Docetaxel; Epirubicin; Female; Fluorodeoxyglucose F18; Fluorouracil; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Letrozole; Lymph Node Excision; Lymph Nodes; Mastectomy; Multimodal Imaging; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Radiotherapy; Ribs; Taxoids; Triazoles; Zoledronic Acid	2017